Pfizer's Acquisition of Hospira Strengthens Its Moat at a Fair Price
February 05, 2015 at 11:57 AM EST
Despite the high 39% premium to Hospira's stock price, we believe the acquisition price is justified based on Pfizer's ability to unlock more value with its global reach.
